Small Molecule Discovery & Mechanistic Validation
VistaraBio’s small-molecule discovery engine reveals how compounds reshape protein networks, substrate logic, and signaling pathways. Our BET inhibitor studies – expanded with SUMO-switch biology and JAK-STAT crosstalk – demonstrates how deep mechanistic insight transforms therapeutic design.
BRD4 Biology Is More Than Bromodomains
BET inhibitors are traditionally framed as bromodomain blockers. VistaraBio’s work shows the biology is far richer – involving BRD4 kinase activity, SUMO-switch regulation, and JAK-STAT pathway crosstalk. Many additional aspects of BET inhibitors were uncovered with our technology.
The Expanse Of BRD4’s Intrinsic Ser/Thr Kinase Activity May Be Underestimated
This discovery reshapes BET inhibitor biology and reveals substrate phosphorylation-dependent substrate classes that drive transcriptional elongation, chromatin remodeling, and inflammatory signaling.
SUMO-Switch Biology
SUMO1 
SUMO2/3 switching controls BRD4 substrate fate, altering stability, chromatin residency, transcriptional output, and substrate routing.
Crosstalk With JAK-STAT Signaling
BRD4 kinase → SUMO-switch → STAT activation creates a feedback loop between BRD4 catalytic activity and cytokine signaling.
VistaraBio BRD4 Kinase Inhibitor Program Summary
VistaraBio is pioneering a new therapeutic axis within BET biology by targeting BRD4’s intrinsic serine/threonine kinase activity, a function historically overshadowed by its bromodomain roles. Our research shows that BRD4 undergoes interaction-driven conformational changes that expose cryptic, conditional drug-binding pockets – structural states that do not appear in traditional static protein models. These transient pockets create a novel opportunity to selectively modulate BRD4’s kinase function without broadly disrupting chromatin engagement.
Using our proprietary peptide discovery technology, we map the substrate-dependent conformational landscape of BRD4, identifying the interaction states that couple directly to its kinase activity. These peptide-guided assays reveal when and how conditional pockets open, enabling us to screen for small molecules that bind only in these specific structural contexts. This approach yields kinase-selective BRD4 inhibitors that avoid the transcriptional shutdown and toxicity associated with classical bromodomain-targeted BET inhibitors.
Suppressing BET toxicity by inhibiting its interaction with toxic proteins
To further refine selectivity and reduce BET footprint, VistaraBio is advancing a parallel macrocyclic chemistry track. Macrocycles enforce precise three-dimensional shape complementarity, allowing us to design compounds that fit BRD4’s conditional pockets with exceptional specificity. This strategy minimizes off-target BET engagement, reduces crosstalk across BRD2/BRD3/BRDT, and preserves essential chromatin functions while modulating pathological BRD4 kinase signaling.
Together, these integrated discovery engines-conditional pocket mapping, kinase-axis screening, and macrocyclic design-form a unified pipeline for first-in-class BRD4 kinase inhibitors. VistaraBio’s goal is to deliver BET therapeutics that are mechanistically precise, footprint-reduced, and clinically differentiated, opening a new chapter in targeting transcriptional and chromatin-linked diseases.
CRL4‑Targeting Compounds: A New Toxicity Frontier & opportunity for detection of NCEs
Our drug‑discovery arm has identified existing marketed drugs that bind non‑CRBN CRL4 subunits.
These molecules exhibit high toxicity, reinforcing a critical point: perturbing CRL4 — at any subunit — is dangerous. This discovery opens a new category of safety liabilities for degrader programs and exploring small‑molecule therapeutics for targeting the CRL4 complex other than with cereblon.